

Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia

A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease)

BACKGROUND: The VANISH trial (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease) compared the effectiveness of escalated antiarrhythmic drug therapy to catheter ablation in patients with prior myocardial infarction, an implanted defibrillator, and ventricular tachycardia (VT). The effectiveness of these interventions in patients on sotalol versus amiodarone was compared.

METHODS AND RESULTS: Analysis was conducted based on whether patients had recurrent VT, despite amiodarone (amio-refractory) or nonamiodarone drugs (sotalol-refractory). Outcomes included death, VT storm, appropriate implantable cardioverter defibrillator shock, and any ventricular arrhythmia. At baseline, 169 (65.2%) were amio-refractory, and 90 (34.7%) were sotalol-refractory (1 patient on procainamide rather than sotalol). Amio-refractory patients had more renal insufficiency (23.7% versus 10%; $P=0.0008$), worse New York Heart Association class (82.3% II/III versus 65.5%; $P=0.0003$), and lower ejection fraction ($29\pm 9.7\%$ versus $35.2\pm 11\%$; $P<0.0001$). Within the amio-refractory group, ablation resulted in reduction of any ventricular arrhythmia compared with escalated drug therapy (hazard ratio, 0.53; 95% confidence interval, 0.31–0.9), $P=0.020$). Sotalol-refractory patients had trends toward higher mortality and VT storm with ablation, with no effect on implantable cardioverter defibrillator shocks. Within the escalated drug therapy arm, amio-refractory patients had a higher rate of the composite outcome (hazard ratio, 1.94; 95% confidence interval, 1.14–3.29; $P=0.0144$) and a trend to higher mortality (hazard ratio, 2.40; 95% confidence interval, 0.93–6.22; $P=0.07$), whereas mortality was not different between amio- and sotalol-refractory patients within the ablation treatment group.

CONCLUSIONS: Patients with amio-refractory VT have a higher rate of ventricular arrhythmia and mortality than those with sotalol-refractory VT and derive greater benefit of catheter ablation than for patients with sotalol-refractory VT who are switched to amiodarone.


CLINICAL TRIAL REGISTRATION: URL: <https://clinicaltrials.gov>. Unique identifier: NCT00905853.

Ratika Parkash, MD, MS
 Isabelle Nault, MD
 Lena Rivard, MD, MSc
 Lorne Gula, MD
 Vidal Essebag, MD, PhD
 Pablo Nery, MD
 Stanley Tung, MD
 Jean-Marc Raymond, MD
 Laurence Sterns, MD
 Steve Doucette, MSc
 George Wells, PhD
 Anthony S.L. Tang, MD
 William G. Stevenson, MD
 John L. Sapp, MD

Correspondence to: Ratika Parkash, MD, MS, Dalhousie University, Room 2501D, 1796 Summer St, Halifax, Nova Scotia B3H 3A7, Canada. E-mail ratika.parkash@nshealth.ca

Key Words: anti-arrhythmia agents ■ catheter ablation ■ humans ■ myocardial infarction ■ ventricular tachycardia

© 2018 American Heart Association, Inc.



WHAT IS KNOWN?

- Catheter ablation has been proven to be superior to antiarrhythmic drugs to prevent recurrent ventricular arrhythmia and death in patients with ischemic heart disease. Treatment-attributed adverse events were also lower with catheter ablation than with escalated drug therapy in these patients.

WHAT THE STUDY ADDS?

- Patients were more ill on amiodarone.
- Mortality was higher in patients on amiodarone but was no longer significant after adjusting for baseline differences.
- In patients on sotalol, amiodarone as the next step in therapy resulted in the same outcomes as ablation, whereas in patients on amiodarone, catheter ablation led to improved outcomes.
- Patients who have failed amiodarone therapy likely have an arrhythmic substrate that will be less responsive to additional medical therapy, and catheter ablation provides the greatest benefit.

Ventricular tachycardia (VT) in the setting of ischemic heart disease is known to portend a poor prognosis.^{1,2} Implantable cardioverter defibrillators (ICDs) have demonstrated a reduction in mortality in the setting of ischemic heart disease both in patients who presented with prior ventricular arrhythmia and those with reduced ejection fraction, found to be at risk.¹⁻⁴ Subsequent analyses have demonstrated that ICD shocks are associated with an increase in mortality⁵⁻⁷ and reduced quality of life.⁸⁻¹⁰ Catheter ablation for patients with ischemic cardiomyopathy and VT despite first-line antiarrhythmic drug therapy was supe-

rior to escalation of antiarrhythmic pharmacotherapy in the VANISH study (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease), with a 28% relative risk reduction in a composite end point of mortality, VT storm, or ICD shock.¹¹ Patients in this study were enrolled with VT occurring during administration of amiodarone (n=169) or nonamiodarone antiarrhythmic drugs (sotalol, n=89; procainamide, n=1); randomization was stratified by whether patients had VT, despite amiodarone (amio-refractory) or nonamiodarone (sotalol-refractory). Sotalol-refractory patients were randomly treated with either amiodarone or catheter ablation, whereas amio-refractory patients were randomly treated with escalated drug dosing (amiodarone reloading and higher dose or addition of mexiletine) or catheter ablation. The amio-refractory group had a greater relative reduction in the primary outcome with catheter ablation compared with the sotalol-refractory group. The influence of baseline antiarrhythmic drug therapy on secondary outcomes has not been described. It remains unclear whether differences in outcome were because of differences in patient characteristics, or because of differences in the treatment regimen, and these issues are addressed by this prespecified analysis.

METHODS

The detailed protocol of the VANISH study has been published previously.¹¹ The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results. Briefly, the VANISH study was a randomized clinical trial, with blinded end-point evaluation of 259 patients with prior myocardial infarction, an ICD, and VT, comparing escalated antiarrhythmic drug therapy (amiodarone 2-300 mg/d±mexiletine 200 mg TID) to catheter ablation with

ongoing antiarrhythmic drug therapy (amiodarone or sotalol). The primary outcome was a composite of time to death, VT storm, or ICD shock for ventricular arrhythmia, after a 30-day treatment period. VT storm was defined as ≥ 3 documented episodes of VT within 24 hours. ICD programming was standardized in all patients. The study took place from July 2009 until November 2014 in 22 centers from Canada, Europe, United States, and Australia. The VANISH study was approved by all participating institutional review committees, and the subjects gave informed consent for their participation.

This study examined all patients enrolled into the study, comparing those who were on amiodarone at baseline (amio-refractory) to the nonamiodarone group (sotalol-refractory). The outcomes are each of the individual components of the primary outcome: death, appropriate ICD shock, and VT storm. The secondary outcomes are also analyzed and include appropriate ICD antitachycardia pacing, inappropriate ICD shocks, and documented sustained VT below detection rate of the ICD. A composite outcome of all ventricular arrhythmia events was also analyzed, which consisted of appropriate ICD shock, appropriate ICD antitachycardia pacing, VT storm, and documented sustained VT below detection rate of the ICD.

Analysis

Baseline demographic information was summarized using descriptive statistics. Categorical data were presented as frequencies and percentages. Continuous data were presented as median with interquartile range or as mean \pm SD depending on the distribution of data. Time-to-event analyses for the secondary end points were performed by censoring at the time of death or study exit.

Survival rates were summarized for escalated antiarrhythmic drug therapy and catheter ablation groups, according to baseline antiarrhythmic drug therapy, using Kaplan–Meier product-limit estimates. Adjusted analyses using the Cox proportional hazards model were performed for the following variables: left ventricular ejection fraction, renal disease, age, sex, β -blocker use, and New York Heart Association class. All analyses were performed in SAS, version 9.4 (SAS Institute, Cary, NC).

RESULTS

There were 169 (65.3%) patients whose qualifying arrhythmia occurred despite administration of amiodarone at the time of entry into the study (the amiodarone-refractory group); 89 (34.3%) patients were on sotalol, and 1 (0.4%) patient was on procainamide, comprising the sotalol-refractory group. The baseline characteristics of the 2 groups are presented in Table 1. The mean age in the amio-refractory and sotalol-refractory groups was 68.4 \pm 8.4 years versus 69.1 \pm 7.7 years ($P=0.49$), respectively. The main differences between the 2 groups were a higher rate of renal insufficiency (23.7% versus 10%; $P=0.008$), higher New York Heart Association class (82.3% II/III versus 65.5%; $P=0.0003$), lower

ejection fraction (29 \pm 9.7 versus 35.2 \pm 11; $P<0.0001$), and higher rate of cardiac resynchronization therapy (25.4% versus 8.9%; $P=0.005$) in the amio-refractory group. Patients in the amio-refractory group at baseline had a lower use of β -blockers (92.3% versus 100%; $P=0.005$), higher use of diuretic (75.1% versus 57.8%; $P=0.005$), and higher use of digoxin (24.3% versus 12.2%; $P=0.02$). In the escalated drug-treated group, there were 11 (6.5%) patients of those on amiodarone who received mexiletine.

Outcomes Within Amio-Refractory and Sotalol-Refractory Groups

Within the amio-refractory patients, there was no significant difference between ablation and escalated drug-treated groups in the time to death (Figure 1A and 1B) or first appropriate ICD shock (Table 2). The ablation-treated patients did have a significant reduction in VT storm (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.26–0.82; $P=0.008$), need for antitachycardia pacing for VT (HR, 0.61; 95% CI, 0.41–0.9; $P=0.12$), and any ventricular arrhythmia (HR, 0.53; 95% CI, 0.31–0.90; $P=0.020$; Figure 2A and 2B). In the sotalol-refractory patients, there were no differences in death, appropriate ICD shock, or any VT, when comparing the catheter ablation to escalated antiarrhythmic drug therapy groups.

Outcomes Between Amio-Refractory and Sotalol-Refractory Groups

In patients treated with ablation, there was no significant difference in mortality comparing the amio-refractory and sotalol-refractory groups (HR, 1.54; 95% CI, 0.74–3.19; $P=0.25$; Table 3). In patients treated with escalated antiarrhythmic drug therapy, a higher mortality rate was seen among amio-refractory patients compared with those in the sotalol-refractory group (HR, 2.73; 95% CI, 1.19–6.26; $P=0.018$); this did not reach statistical significance in the adjusted multivariate model (HR, 2.4; 95% CI, 0.93–6.22; $P=0.07$; Table 4). There was no difference in recurrent ventricular arrhythmias except for a higher rate of antitachycardia pacing for VT in the amio-refractory group (HR, 1.93; 95% CI, 1.11–3.36; $P=0.020$), when treated with escalated antiarrhythmic drugs. When comparing all patients in the amio-refractory group to all patients in the sotalol-refractory group, there was a higher rate of mortality (HR, 2.03; 95% CI, 1.18–3.51; $P=0.011$) and appropriate ICD shock (HR, 1.57; 95% CI, 1.03–2.41; $P=0.037$) in the amio-refractory group (Table 5). When adjusted for baseline characteristics, these differences in mortality were no longer significant (HR, 1.44; 95% CI, 0.79–2.63; $P=0.24$).

Table 1. Characteristics of the 2 Groups by Baseline Antiarrhythmic Drug Use

| Characteristics* | Amiodarone (N=169) | Sotalol (N=90) | P Value |
|--|--------------------|----------------|---------|
| Age, y† | 68.4±8.4 | 69.1±7.7 | 0.49 |
| Male sex, n (%) | 157 (92.9%) | 84 (93.3%) | 1 |
| Time since last MI, y | 15.3±9.5 | 16.4±9.7 | 0.39 |
| Prior PCI, n (%) | 72 (42.6%) | 40 (44.4%) | 0.79 |
| Prior coronary artery bypass surgery, n (%) | 79 (46.7%) | 39 (43.3%) | 0.69 |
| Diabetes mellitus, n (%) | 52 (30.8%) | 25 (27.8%) | 0.67 |
| Hypertension, n (%) | 116 (68.6%) | 64 (71.1%) | 0.78 |
| Renal insufficiency, n (%) | 40 (23.7%) | 9 (10%) | 0.008 |
| Atrial fibrillation or atrial flutter, n (%) | 72 (42.6%) | 27 (30%) | 0.06 |
| NYHA FC, n (%) | | | |
| I | 30 (17.8%) | 31 (34.4%) | 0.0003 |
| II | 88 (52.1%) | 49 (54.4%) | |
| III | 51 (30.2%) | 10 (11.1%) | |
| Ejection fraction, % | 29±9.7 | 35.2±11 | <0.0001 |
| Single-chamber ICD, n (%) | 55 (32.5%) | 32 (35.6%) | 0.005 |
| Dual-chamber ICD, n (%) | 71 (42%) | 50 (55.6%) | |
| CRT defibrillator, n (%) | 43 (25.4%) | 8 (8.9%) | |
| Medication use | | | |
| Antiarrhythmic drug at time of qualification | | | |
| Nonamiodarone, n (%) | | | |
| Sotalol, n (%) | NA | 89 (98.9%) | NA |
| Procainamide, n (%) | NA | 1 (1.1%) | |
| Amiodarone, n (%) | 169 (100%) | 0 (0%) | NA |
| Dose <300 mg/d | 150 (88.8%) | NA | |
| Dose ≥300 mg/d, n (%) | 19 (11.2%) | NA | |
| Other medications | | | |
| β-Blocker, n (%)* | 156 (92.3%) | 90 (100%) | 0.005 |
| ACE inhibitor, n (%) | 109 (64.5%) | 59 (65.6%) | 0.89 |
| ARB, n (%) | 37 (21.9%) | 22 (24.4%) | 0.64 |
| Diuretic, n (%) | 127 (75.1%) | 52 (57.8%) | 0.005 |
| Digoxin, n (%) | 41 (24.3%) | 11 (12.2%) | 0.02 |
| Aspirin, n (%) | 126 (81.3%) | 58 (77.3%) | 0.49 |
| Calcium channel blocker, n (%) | 22 (13%) | 11 (12.2%) | 1 |
| Warfarin, n (%) | 64 (40.8%) | 25 (33.8%) | 0.38 |
| Nonwarfarin anticoagulant, n (%) | 15 (8.9%) | 8 (8.9%) | 1 |
| Estimated GFR (Cockcroft–Gault) | 68.5±27.9 | 87±25.5 | <0.0001 |

(Continued)

Table 1. Continued

| Characteristics* | Amiodarone (N=169) | Sotalol (N=90) | P Value |
|-------------------|--------------------|----------------|---------|
| Sodium, mmol/L | 138.5±3.3 | 138.3±2.9 | 0.61 |
| Potassium, mmol/L | 4.3±0.4 | 4.3±0.45 | 0.99 |
| NT-proBNP, pg/mL | 1181.8±1226.9 | 586.0±573.2 | <0.0001 |

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; GFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA FC, New York Heart Association functional class; and PCI, percutaneous coronary intervention.

*Plus-minus values are means±SD; median and interquartile ranges are shown when indicated; categorical values are n (%).

†The qualifying event occurred during procainamide administration for 1 patient.

DISCUSSION

Patients enrolled in the VANISH study were stratified by whether the qualifying arrhythmia occurred despite amiodarone versus nonamiodarone drug and the analysis of the difference in the primary outcome between strata was prespecified. In this substudy, we found that patients with amio-refractory VT at baseline who were treated with escalated drug therapy had substantially higher rates of death and ventricular arrhythmia than the sotalol-refractory group. Among patients treated with catheter ablation, these differences were no longer evident. The differing effects on mortality, with a trend toward harm with catheter ablation in the sotalol-refractory group, as compared with a trend toward benefit with ablation in the amio-refractory group are intriguing although not statistically significant. Patients with amio-refractory VT have a higher level of comorbidity, including worse New York Heart Association class, more renal insufficiency, and lower ejection fraction. This higher level of comorbidity in the amio-refractory group was associated with higher rates of mortality and recurrence of ventricular arrhythmia. Pre-enrollment drug status was no longer independently predictive of outcome once adjustment for these comorbidities was performed. These subgroups are too small to draw firm conclusions about effects on mortality.

Amiodarone is a powerful antiarrhythmic drug and has been shown to reduce VT in prior studies of ventricular arrhythmia, in the presence of an ICD (HR, 0.27; $P<0.001$).¹ It is substantially better than any other drug for the reduction of VT¹² but is plagued by the risk of complications during longer term administration. When used as preventive therapy for patients with heart failure, it has resulted in reductions in sudden arrhythmic death but no effect on overall mortality.^{4,5,12,13} In the SCD-HeFT trial (Sudden Cardiac Death in Heart Failure Trial), patients with reduced ejection fraction and heart failure were randomly allocated to placebo, amiodarone, or ICD implant, stratified by functional class. In the functional class III stratum, amiodarone was associated with increased mortality¹⁴ suggesting that some of




Figure 1. Mortality rate in the ablation (solid line) vs the escalated antiarrhythmic drug (dotted line) group.

A, Amio-refractory group (hazard ratio, 0.8; 95% confidence interval [CI], 0.47–1.36; $P=0.41$). **B**, Sotalol-refractory group (hazard ratio, 1.49; 95% CI, 0.57–3.94; $P=0.42$).

amiodarone's benefit is offset by harm. Potential amiodarone side effects are numerous and often relate to longer term exposure. In a summary of trials studying amiodarone for the primary prevention of sudden death with varying follow-up, pulmonary toxicity was seen in 2.9%, thyroid toxicity in 3.6%, hepatic toxicity in 1.8%, and

bradycardia in 2.8% during 12 to 46 months of follow-up.¹⁵ It is possible that the differential impact of higher dose amiodarone in comparison with catheter ablation is because of the drug itself in patients with more advanced heart failure as observed in the SCD-HeFT trial and that catheter ablation is thus more effective, but it

Table 2. Outcomes by Randomized Groups According to Baseline Antiarrhythmic Drug Strata

| Outcome | Amio-Refractory (N=169) | | | | Sotalol-Refractory (N=90) | | | |
|--------------------------------------|-------------------------|-------------------------------|------------------|---------|---------------------------|-------------------------------|------------------|---------|
| | Ablation (n=85) | Escalated Drug Therapy (n=84) | HR (95% CI) | P Value | Ablation (n=47) | Escalated Drug Therapy (n=43) | HR (95% CI) | P Value |
| Death | 26 (30.6%) | 28 (33.3%) | 0.8 (0.47–1.36) | 0.41 | 10 (21.3%) | 7 (16.3%) | 1.49 (0.57–3.94) | 0.42 |
| Death (person-years, 95% CI) | 13.8 (8.5–19.0) | 16.5 (11.0–23.8) | ... | ... | 8.6 (4.1–15.9) | 6.0 (2.4–12.3) | ... | ... |
| Appropriate ICD shock | 35 (41.2%) | 39 (46.4%) | 0.7 (0.44–1.11) | 0.13 | 15 (31.9%) | 15 (34.9%) | 0.87 (0.43–1.79) | 0.71 |
| VT storm | 19 (22.4%) | 31 (36.9%) | 0.46 (0.26–0.82) | 0.008 | 13 (27.7%) | 11 (25.6%) | 1.26 (0.56–2.81) | 0.58 |
| Appropriate ICD ATP | 49 (57.7%) | 57 (67.9%) | 0.61 (0.41–0.9) | 0.012 | 28 (59.6%) | 21 (48.8%) | 1.55 (0.87–2.76) | 0.14 |
| Inappropriate ICD shocks | 4 (4.7%) | 7 (8.3%) | 0.48 (0.14–1.64) | 0.24 | 9 (19.2%) | 4 (9.3%) | 1.85 (0.56–6.15) | 0.31 |
| Documented sustained VT below detect | 3 (3.5%) | 5 (6%) | 0.51 (0.12–2.15) | 0.36 | 0 (0%) | 3 (7%) | NA | NA |
| Composite ventricular arrhythmia* | 23 (27.1%) | 35 (41.7%) | 0.53 (0.31–0.9) | 0.020 | 20 (42.6%) | 16 (37.2%) | 1.32 (0.69–2.56) | 0.40 |

ATP indicates antitachycardia pacing; CI, confidence interval; HR, hazard ratio; ICD, implantable cardioverter defibrillator; and VT, ventricular tachycardia.

*Consists of appropriate ICD shock, appropriate ICD antitachycardia pacing, VT storm, and documented sustained VT below detection rate of the ICD.




Figure 2. Rate of composite ventricular arrhythmia in the ablation (solid line) vs the escalated antiarrhythmic drug (dotted line) group. **A**, Amio-refractory group (hazard ratio, 0.53; 95% confidence interval [CI], 0.31–0.9; $P=0.020$). **B**, Sotalol-refractory group (hazard ratio, 1.32; 95% CI, 0.69–2.56; $P=0.40$).

is also possible that it is the comorbidities of patients who receive amiodarone therapy that drive their outcomes or that amiodarone administration affects catheter ablation outcomes. In the VANISH study, there were

significantly more treatment-attributed adverse events in the escalated drug therapy group including nonfatal hepatic dysfunction, tremor, and drug intolerance (51 events versus 22 events in the ablation group; $P=0.002$).

Table 3. Outcomes by Baseline Antiarrhythmic Drug Within Ablation Arm

| Outcome | Amio-Refractory (n=85) | Sotalol-Refractory (n=47) | Adjusted HR* (95% CI) | P Value |
|--------------------------------------|------------------------|---------------------------|-----------------------|---------|
| | N (%) | N (%) | | |
| Death | 26 (30.6%) | 10 (21.3%) | 1.08 (0.48–2.4) | 0.86 |
| Appropriate ICD shock | 35 (41.2%) | 15 (31.9%) | 1.2 (0.61–2.36) | 0.61 |
| VT storm | 19 (22.4%) | 13 (27.7%) | 0.8 (0.37–1.75) | 0.58 |
| Appropriate ICD ATP | 49 (57.7%) | 28 (59.6%) | 0.88 (0.52–1.49) | 0.64 |
| Inappropriate ICD shocks | 4 (4.7%) | 9 (19.2%) | 0.41 (0.1–1.74) | 0.23 |
| Documented sustained VT below detect | 3 (3.5%) | 0 (0%) | NA | NA |
| Composite ventricular arrhythmia† | 23 (27.1%) | 20 (42.6%) | 0.65 (0.33–1.29) | 0.22 |

ATP indicates antitachycardia pacing; CI, confidence interval; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; and VT, ventricular tachycardia.

*Adjusted for baseline variables, including left ventricular ejection fraction, NYHA, renal insufficiency, and β -blockers.

†Consists of appropriate ICD shock, appropriate ICD antitachycardia pacing, VT storm, and documented sustained VT below detection rate of the ICD.

Table 4. Outcomes by Baseline Antiarrhythmic Drug Within Escalated Drug Therapy Arm

| Outcome | Amio-Refractory (n=84) | Sotalol-Refractory (n=43) | Adjusted HR* (95% CI) | Log-Rank |
|--------------------------------------|------------------------|---------------------------|-----------------------|----------|
| | N (%) | N (%) | | P Value |
| Death | 28 (33.3) | 7 (16.3) | 2.4 (0.93–6.22) | 0.07 |
| Appropriate ICD shock | 39 (46.4) | 15 (34.9) | 1.59 (0.82–3.07) | 0.17 |
| VT storm | 31 (36.9) | 11 (25.6) | 1.69 (0.77–3.69) | 0.19 |
| Appropriate ICD ATP | 57 (67.9) | 21 (48.8) | 1.93 (1.11–3.36) | 0.020 |
| Inappropriate ICD shocks | 7 (8.3) | 4 (9.3) | 0.69 (0.15–3.2) | 0.63 |
| Documented sustained VT below detect | 5 (6) | 3 (7) | 0.72 (0.11–4.53) | 0.72 |
| Composite ventricular arrhythmia† | 35 (41.7) | 16 (37.2) | 1.11 (0.58–2.15) | 0.75 |

ATP indicates antitachycardia pacing; CI, confidence interval; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; and VT, ventricular tachycardia.

*Adjusted for baseline variables, including left ventricular ejection fraction, NYHA, renal insufficiency, and β -blockers.

†Consists of appropriate ICD shock, appropriate ICD antitachycardia pacing, VT storm, and documented sustained VT below detection rate of the ICD.

Whether these adverse events have a long-term effect on mortality is unclear.¹¹

In contrast, sotalol does not result in the same degree of benefit in reduction of ventricular arrhythmia. The OPTIC trial (Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients) randomized patients with ventricular arrhythmia to β -blocker, sotalol, or amiodarone. Patients on sotalol had a nonsignificant reduction in ICD shocks (HR, 0.61; $P=0.055$).¹² A single study by Pacifico et al¹⁶ demonstrated a significant reduction in recurrent VT with sotalol (49% relative risk reduction; $P<0.001$). Other smaller, ($n\leq 100$) single-center trials previously estimated the relative reduction in VT with sotalol at 39% in comparison with placebo¹⁷ or found either a neutral or increased risk in comparison with β -blockers.^{18,19} Sotalol has been similar to other antiarrhythmic drugs, conferring a risk of ventricular proarrhythmia concomitantly with its benefit¹³ but is considered to have a relatively good safety profile and is thus a frequent choice for first-line therapy for patients

without high risk of sotalol-induced proarrhythmia.²⁰ In this study, the continuation of sotalol in the catheter ablation group may have contributed to a trend toward an increase in mortality, as compared with continuing and not escalating amiodarone (200 mg/d). Alternatively, it is possible that the difference in trends was either because of chance or because of a risk associated with catheter ablation.

This study provides important insight into which patients might benefit the most from catheter ablation. We have demonstrated that patients who have failed amiodarone therapy likely have an arrhythmic substrate that will be less responsive to escalating medical therapy, and catheter ablation provides greater benefit. Interestingly, catheter ablation seems to have similar efficacy to initiation of amiodarone for patients who are having recurrent VT, despite therapy with sotalol, but this observation is limited to the follow-up available in the present study. Longer follow-up may detect the risk associated with long-term use of high-dose amioda-

Table 5. Overall Outcomes According to Baseline Antiarrhythmic Drug

| Outcome | Amio-Refractory (n=169) | Sotalol-Refractory (n=90) | Unadjusted HR (95% CI) | Unadjusted P Value | Adjusted HR* (95% CI) | P Value |
|--|-------------------------|---------------------------|------------------------|--------------------|-----------------------|---------|
| | N (%) | N (%) | | | | |
| Composite of death, appropriate ICD shock and VT storm | 117 (69.2%) | 48 (53.3%) | 1.54 (1.1–2.16) | 0.012 | 1.36 (0.94–1.96) | 0.10 |
| Death | 54 (32%) | 17 (18.9%) | 2.03 (1.18–3.51) | 0.011 | 1.44 (0.79–2.63) | 0.24 |
| Appropriate ICD shock | 74 (43.8%) | 30 (33.3%) | 1.57 (1.03–2.41) | 0.037 | 1.39 (0.87–2.22) | 0.16 |
| VT storm | 50 (29.6%) | 24 (26.7%) | 1.24 (0.76–2.01) | 0.39 | 1.11 (0.65–1.92) | 0.70 |
| Appropriate ATP | 49 (57.7%) | 28 (59.6%) | 1.34 (0.95–1.89) | 0.094 | 1.27 (0.87–1.84) | 0.22 |
| Inappropriate ICD shocks | 4 (4.7%) | 9 (19.2%) | 0.49 (0.22–1.08) | 0.078 | 0.48 (0.17–1.33) | 0.16 |
| Documented sustained VT below detect | 3 (3.5%) | 0 (0%) | 1.57 (0.42–5.93) | 0.50 | 1.13 (0.21–6.16) | 0.89 |
| Composite ventricular arrhythmia† | 23 (27.1%) | 20 (42.6%) | 0.86 (0.57–1.31) | 0.49 | 0.84 (0.52–1.34) | 0.46 |

ATP indicates antitachycardia pacing; CI, confidence interval; HR, hazard ratio; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; and VT, ventricular tachycardia.

*Adjusted for baseline variables, including left ventricular ejection fraction, NYHA, renal insufficiency, and β -blockers.

†Consists of appropriate ICD shock, appropriate ICD antitachycardia pacing, VT storm, and documented sustained VT below detection rate of the ICD.

rone. Clinical decisions in this setting may need to consider the initial procedural risk of catheter ablation in comparison with the longer term risks associated with amiodarone therapy. Patient preferences, comorbidities, individualized procedural risk assessment, and estimated prognosis may all need to be taken into account to identify the optimal therapy for a patient with recurrent ventricular arrhythmias, despite nonamiodarone antiarrhythmic drug therapy.

There are limitations to the interpretation of these findings, including the relatively small number of patients and events in each group. Using adjusted analysis, we attempted to account for baseline differences in amio-refractory versus sotalol-refractory patients; nonetheless, this adjustment may be incomplete. The findings remain exploratory but provide useful insight into the relative effects of catheter ablation to antiarrhythmic drug therapy in the ischemic population.

CONCLUSION

Catheter ablation provides greater relative benefit than escalation of antiarrhythmic drug therapy for patients who experience recurrent VT, despite chronic oral amiodarone therapy, with the greatest effect on reduction of VT storm. In contrast, outcomes of ablation are similar to those of initiating chronic amiodarone therapy for patients who are failing sotalol.

ACKNOWLEDGMENTS

We gratefully acknowledge the major contributions of Karen Giddens to the conduct of the trial. Drs Parkash, Gula, Nery, Tang, Wells, and Sapp are Network Investigators of the Cardiac Arrhythmia Network of Canada.

SOURCES OF FUNDING

This study was funded by the Canadian Institutes of Health Research, with additional financial support from St. Jude Medical and Johnson & Johnson Medical Products.

DISCLOSURES

Dr Parkash has received research grants from Medtronic and Abbott Medical. Dr Sapp has received funding from Abbott Medical. Dr Essebag has received modest honoraria from Medtronic, Abbott, Biosense, and Boston Scientific. Dr Stevenson has received modest research support from Abbott and Biosense Webster. The other authors report no conflicts.

AFFILIATIONS

From the QEII Health Sciences Centre, Halifax, Nova Scotia, Canada (R.P., J.L.S.); Dalhousie University, Halifax, Nova Sco-

tia, Canada (R.P., J.L.S.); Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Canada (I.N.); Montreal Heart Institute, Quebec, Canada (L.R.); University of Western Ontario, London, Canada (L.G., A.S.L.T.); McGill University Health Center, Montreal, Quebec, Canada (V.E.); Hôpital Sacré-Coeur de Montréal, Quebec, Canada (V.E.); University of Ottawa Heart Institute, Ontario, Canada (P.N., G.W.); Royal Columbian Hospital, Vancouver, British Columbia, Canada (S.T.); Centre Hospitalier de L'Université de Montréal, Quebec, Canada (J.-M.R.); Royal Jubilee Hospital, Victoria, British Columbia, Canada (L.S.); Research Methods Unit, Dalhousie University, Halifax, Nova Scotia, Canada (S.D.); and Brigham and Women's Hospital, Boston, MA (W.G.S.).

FOOTNOTES

Received July 19, 2017; accepted November 25, 2017.

Circ Arrhythm Electrophysiol is available at <http://circep.ahajournals.org>.

REFERENCES

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med*. 1997;337:1576–1583. doi: 10.1056/NEJM199711273372202.
2. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, Green MS, Klein GJ, O'Brien B. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. *Circulation*. 2000;101:1297–1302.
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*. 2002;346:877–883. doi: 10.1056/NEJMoa013474.
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. 2005;352:225–237. doi: 10.1056/NEJMoa043399.
5. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. *Circulation*. 2004;110:3760–3765. doi: 10.1161/01.CIR.0000150390.04704.B7.
6. Exner DV, Pinski SL, Wyse DG, Renfro EG, Follmann D, Gold M, Beckman KJ, Coromilas J, Lancaster S, Hallstrom AP; AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators. Electrical storm presages nonsudden death: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. *Circulation*. 2001;103:2066–2071.
7. Abdelwahab AM, MacIntyre CJ, Parkash R, Basta MN, Gardner MJ, Liu A, Sapp J. Predictors of mortality in patients with recurrent ICD shocks. *Can J Cardiol*. 2007;23:191C.
8. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M, Newman D, Connolly SJ. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). *Am Heart J*. 2002;144:282–289.
9. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. *Pacing Clin Electrophysiol*. 1999;22:1305–1313.
10. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF, Kadish A. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. *Arch Intern Med*. 2007;167:2226–2232. doi: 10.1001/archinte.167.20.2226.

11. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, Thibault B, Rivard L, Gula L, Leong-Sit P, Essebag V, Nery PB, Tung SK, Raymond JM, Sterns LD, Veenhuyzen GD, Healey JS, Redfearn D, Roux JF, Tang AS. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. *N Engl J Med*. 2016;375:111–121. doi: 10.1056/NEJMoa1513614.
12. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Couto B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. *JAMA*. 2006;295:165–171. doi: 10.1001/jama.295.2.165.
13. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. *Circulation*. 2002;105:589–594.
14. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, Estes NA III, Greenberg H, Hall WJ, Huang DT, Kautzner J, Klein H, McNitt S, Olshansky B, Shoda M, Wilber D, Zareba W; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. *N Engl J Med*. 2012;367:2275–2283. doi: 10.1056/NEJMoa1211107.
15. Santangeli P, Di Biase L, Burkhardt JD, Bai R, Mohanty P, Pump A and Natale A. Examining the safety of amiodarone. *Expert Opin Drug Saf*. 2012;11:191–214.
16. Pacifico A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD and Prystowsky EN. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. *N Engl J Med*. 1999;340:1855–1862.
17. Kuhlkamp V, Mewis C, Mermi J, Bosch RF and Seipel L. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. *J Am Coll Cardiol*. 1999;33:46–52.
18. Seidl K, Hauer B, Schwick NG, Zahn R and Senges J. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. *Am J Cardiol*. 1998;82:744–748.
19. Kettering K, Mewis C, Dornberger V, Vonthein R, Bosch RF and Kuhlkamp V. Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. *Pacing Clin Electrophysiol*. 2002;25:1571–1576.
20. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, Dorian P, Huikuri H, Kim YH, Knight B, Marchlinski F, Ross D, Sacher F, Sapp J, Shivkumar K, Soejima K, Tada H, Alexander ME, Triedman JK, Yamada T, Kirchhof P, Lip GY, Kuck KH, Mont L, Haines D, Indik J, Dimarco J, Exner D, Iesaka Y, Savelieva I and Ep-Europace UK. EHRA/HRS/APHS expert consensus on ventricular arrhythmias. *Heart Rhythm*. 2014;11:e166–196.

Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease)

Ratika Parkash, Isabelle Nault, Lena Rivard, Lorne Gula, Vidal Essebag, Pablo Nery, Stanley Tung, Jean-Marc Raymond, Laurence Sterns, Steve Doucette, George Wells, Anthony S.L. Tang, William G. Stevenson and John L. Sapp

Circ Arrhythm Electrophysiol. 2018;11:
doi: 10.1161/CIRCEP.117.005663

Circulation: Arrhythmia and Electrophysiology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circep.ahajournals.org/content/11/1/e005663>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Arrhythmia and Electrophysiology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation: Arrhythmia and Electrophysiology* is online at:
<http://circep.ahajournals.org/subscriptions/>